Yousem D M, Arrington J A, Zinreich S J, Kumar A J, Bryan R N
Division of Neuroradiology, Johns Hopkins Medical Institutions, Baltimore.
Radiology. 1989 Jan;170(1 Pt 1):239-43. doi: 10.1148/radiology.170.1.2909102.
Magnetic resonance (MR) images of 68 patients examined for adenomas of the pituitary gland were retrospectively reviewed for the presence of hyperintensity on T1-weighted images because of recent reports suggesting that bromocriptine treatment may affect T1 values. Twenty-seven patients were examined after either surgery or radiation therapy, 29 were receiving bromocriptine, and 22 had not received any treatment at the time of MR imaging. MR imaging criteria showed evidence of subacute or chronic intratumoral hemorrhage in 18 patients, five of whom had hemorrhage proved at surgery. Ten of the 18 patients were asymptomatic from the hemorrhage; eight had headaches, visual field cuts, or cranial nerve deficits. Although an increased frequency of intratumoral hemorrhage was noted in prolactinomas and macroadenomas and in patients undergoing bromocriptine therapy, the effect of bromocriptine on bleeding was the only significant correlation (P less than .01).
对68例因垂体腺瘤接受检查的患者的磁共振（MR）图像进行回顾性分析，以观察T1加权图像上是否存在高信号，因为最近有报道提示溴隐亭治疗可能会影响T1值。27例患者在手术或放疗后接受检查，29例正在接受溴隐亭治疗，22例在MR成像时未接受任何治疗。MR成像标准显示18例患者有亚急性或慢性瘤内出血迹象，其中5例在手术中证实有出血。18例患者中有10例出血无症状；8例有头痛、视野缺损或颅神经功能障碍。虽然在泌乳素瘤、大腺瘤以及接受溴隐亭治疗的患者中瘤内出血频率增加，但溴隐亭对出血的影响是唯一具有显著相关性的因素（P小于0.01）。
